1.
Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1.
Markets Covered
1.2.2.
Years Considered for
Study
1.2.3.
Key Market
Segmentations
2.
Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3.
Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and
Trends
4.
Voice of Customer
5.
Global Hepatitis C Market Outlook
5.1. Market Size & Forecast
5.1.1.
By Value
5.2. Market Share & Forecast
5.2.1.
By Type (Acute Hepatitis C, Chronic Hepatitis C, Others)
5.2.2.
By Treatment (Antiviral Drugs, Vaccine, Immune Modulator
Drugs, Surgery, Others)
5.2.3.
By Diagnosis (Liver Biopsy, Blood Tests, Imaging Tests,
Others)
5.2.4.
By Route of Administration (Oral, Parenteral, Others)
5.2.5.
By Distribution Channel (Hospital Pharmacy, Retail
Pharmacy, Online Pharmacy, Others)
5.2.6.
By Company (2023)
5.2.7. By
Region
5.3. Market Map
6.
North America Hepatitis
C Market Outlook
6.1. Market Size & Forecast
6.1.1.
By Value
6.2. Market Share & Forecast
6.2.1.
By Type
6.2.2.
By Treatment
6.2.3.
By Diagnosis
6.2.4.
By Route of Administration
6.2.5. By
Distribution Channel
6.2.6.
By Country
6.3. North America: Country Analysis
6.3.1.
United States Hepatitis
C Market Outlook
6.3.1.1.
Market Size & Forecast
6.3.1.1.1.
By Value
6.3.1.2.
Market Share & Forecast
6.3.1.2.1.
By Type
6.3.1.2.2.
By Treatment
6.3.1.2.3.
By Diagnosis
6.3.1.2.4.
By Route of
Administration
6.3.1.2.5.
By Distribution
Channel
6.3.2.
Mexico Hepatitis C
Market Outlook
6.3.2.1.
Market Size & Forecast
6.3.2.1.1.
By Value
6.3.2.2.
Market Share & Forecast
6.3.2.2.1.
By Type
6.3.2.2.2.
By Treatment
6.3.2.2.3.
By Diagnosis
6.3.2.2.4.
By Route of
Administration
6.3.2.2.5.
By Distribution
Channel
6.3.3.
Canada Hepatitis C
Market Outlook
6.3.3.1.
Market Size & Forecast
6.3.3.1.1.
By Value
6.3.3.2.
Market Share & Forecast
6.3.3.2.1.
By Type
6.3.3.2.2.
By Treatment
6.3.3.2.3.
By Diagnosis
6.3.3.2.4.
By Route of Administration
6.3.3.2.5.
By Distribution
Channel
7.
Europe Hepatitis C
Market Outlook
7.1. Market Size & Forecast
7.1.1.
By Value
7.2. Market Share & Forecast
7.2.1.
By Type
7.2.2.
By Treatment
7.2.3.
By Diagnosis
7.2.4.
By Route of Administration
7.2.5.
By Distribution Channel
7.2.6.
By Country
7.3. Europe: Country Analysis
7.3.1.
France Hepatitis C
Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Type
7.3.1.2.2.
By Treatment
7.3.1.2.3.
By Diagnosis
7.3.1.2.4.
By Route of
Administration
7.3.1.2.5.
By Distribution
Channel
7.3.2.
Germany Hepatitis C
Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Type
7.3.2.2.2.
By Treatment
7.3.2.2.3.
By Diagnosis
7.3.2.2.4.
By Route of
Administration
7.3.2.2.5.
By Distribution
Channel
7.3.3.
United Kingdom Hepatitis
C Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Type
7.3.3.2.2.
By Treatment
7.3.3.2.3.
By Diagnosis
7.3.3.2.4.
By Route of Administration
7.3.3.2.5.
By Distribution
Channel
7.3.4.
Italy Hepatitis C
Market Outlook
7.3.4.1.
Market Size & Forecast
7.3.4.1.1.
By Value
7.3.4.2.
Market Share & Forecast
7.3.4.2.1.
By Type
7.3.4.2.2.
By Treatment
7.3.4.2.3.
By Diagnosis
7.3.4.2.4.
By Route of
Administration
7.3.4.2.5.
By Distribution
Channel
7.3.5.
Spain Hepatitis C
Market Outlook
7.3.5.1.
Market Size & Forecast
7.3.5.1.1.
By Value
7.3.5.2.
Market Share & Forecast
7.3.5.2.1.
By Type
7.3.5.2.2.
By Treatment
7.3.5.2.3.
By Diagnosis
7.3.5.2.4.
By Route of
Administration
7.3.5.2.5.
By Distribution
Channel
8.
Asia-Pacific Hepatitis
C Market Outlook
8.1. Market Size & Forecast
8.1.1.
By Value
8.2. Market Share & Forecast
8.2.1.
By Type
8.2.2.
By Treatment
8.2.3.
By Diagnosis
8.2.4.
By Route of Administration
8.2.5.
By Distribution Channel
8.2.6.
By Country
8.3. Asia-Pacific: Country Analysis
8.3.1.
China Hepatitis C
Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Type
8.3.1.2.2.
By Treatment
8.3.1.2.3.
By Diagnosis
8.3.1.2.4.
By Route of
Administration
8.3.1.2.5.
By Distribution
Channel
8.3.2.
India Hepatitis C
Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Type
8.3.2.2.2.
By Treatment
8.3.2.2.3.
By Diagnosis
8.3.2.2.4.
By Route of
Administration
8.3.2.2.5.
By Distribution
Channel
8.3.3.
South Korea Hepatitis
C Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Type
8.3.3.2.2.
By Treatment
8.3.3.2.3.
By Diagnosis
8.3.3.2.4.
By Route of
Administration
8.3.3.2.5.
By Distribution
Channel
8.3.4.
Japan Hepatitis C
Market Outlook
8.3.4.1.
Market Size & Forecast
8.3.4.1.1.
By Value
8.3.4.2.
Market Share & Forecast
8.3.4.2.1.
By Type
8.3.4.2.2.
By Treatment
8.3.4.2.3.
By Diagnosis
8.3.4.2.4.
By Route of
Administration
8.3.4.2.5.
By Distribution
Channel
8.3.5.
Australia Hepatitis
C Market Outlook
8.3.5.1.
Market Size & Forecast
8.3.5.1.1.
By Value
8.3.5.2.
Market Share & Forecast
8.3.5.2.1.
By Type
8.3.5.2.2.
By Treatment
8.3.5.2.3.
By Diagnosis
8.3.5.2.4.
By Route of
Administration
8.3.5.2.5.
By Distribution
Channel
9.
South America Hepatitis
C Market Outlook
9.1. Market Size & Forecast
9.1.1.
By Value
9.2. Market Share & Forecast
9.2.1.
By Type
9.2.2.
By Treatment
9.2.3.
By Diagnosis
9.2.4.
By Route of Administration
9.2.5.
By Distribution Channel
9.2.6.
By Country
9.3. South America: Country Analysis
9.3.1.
Brazil Hepatitis C
Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Type
9.3.1.2.2.
By Treatment
9.3.1.2.3.
By Diagnosis
9.3.1.2.4.
By Route of
Administration
9.3.1.2.5.
By Distribution
Channel
9.3.2.
Argentina Hepatitis
C Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Type
9.3.2.2.2.
By Treatment
9.3.2.2.3.
By Diagnosis
9.3.2.2.4.
By Route of
Administration
9.3.2.2.5.
By Distribution
Channel
9.3.3.
Colombia Hepatitis C
Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Type
9.3.3.2.2.
By Treatment
9.3.3.2.3.
By Diagnosis
9.3.3.2.4.
By Route of Administration
9.3.3.2.5.
By Distribution
Channel
10.
Middle East and
Africa Hepatitis C Market Outlook
10.1.
Market Size &
Forecast
10.1.1. By Value
10.2.
Market Share &
Forecast
10.2.1.
By Type
10.2.2.
By Treatment
10.2.3.
By Diagnosis
10.2.4.
By Route of Administration
10.2.5.
By Distribution Channel
10.2.6. By Country
10.3.
MEA: Country Analysis
10.3.1. South Africa Hepatitis C Market Outlook
10.3.1.1.
Market Size & Forecast
10.3.1.1.1.
By Value
10.3.1.2.
Market Share & Forecast
10.3.1.2.1.
By Type
10.3.1.2.2.
By Treatment
10.3.1.2.3.
By Diagnosis
10.3.1.2.4.
By Route of
Administration
10.3.1.2.5.
By Distribution
Channel
10.3.2. Saudi Arabia Hepatitis C Market Outlook
10.3.2.1.
Market Size & Forecast
10.3.2.1.1.
By Value
10.3.2.2.
Market Share & Forecast
10.3.2.2.1.
By Type
10.3.2.2.2.
By Treatment
10.3.2.2.3.
By Diagnosis
10.3.2.2.4.
By Route of
Administration
10.3.2.2.5.
By Distribution
Channel
10.3.3. UAE Hepatitis C Market Outlook
10.3.3.1.
Market Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2.
Market Share & Forecast
10.3.3.2.1.
By Type
10.3.3.2.2.
By Treatment
10.3.3.2.3.
By Diagnosis
10.3.3.2.4.
By Route of
Administration
10.3.3.2.5.
By Distribution
Channel
11. Market Dynamics
11.1.
Drivers
11.2.
Challenges
12. Market Trends & Developments
12.1.
Merger &
Acquisition (If Any)
12.2.
Product Launches (If
Any)
12.3.
Recent Developments
13. Porters Five Forces Analysis
13.1.
Competition in the
Industry
13.2.
Potential of New
Entrants
13.3.
Power of Suppliers
13.4.
Power of Customers
13.5.
Threat of Substitute
Products
14. Competitive Landscape
14.1.
Pfizer Inc.
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Products & Services
14.1.4. Financials (As Reported)
14.1.5. Recent Developments
14.1.6. Key Personnel Details
14.1.7. SWOT Analysis
14.2.
GlaxoSmithKline plc
14.3.
Novartis AG
14.4.
Mylan N.V.
14.5.
Teva Pharmaceutical
Industries Ltd.
14.6.
Boehringer Ingelheim
International GmbH
14.7.
Bayer AG
14.8.
Merck & Co.,
Inc.
14.9.
F. Hoffmann-La Roche
AG
14.10.
Bristol-Myers Squibb
Company
15. Strategic Recommendations
16. About Us & Disclaimer